27 October 2021 in npj Precision Oncology
Glioblastoma is the most malignant primary brain tumor and is still in need of effective medical treatment. We isolated patient-derived glioblastoma cells showing high GD2 antigen expression representing a potential target for CAR T strategy. Data highlighted a robust GD2 CAR antitumor potential in 2D and 3D glioblastoma models associated with a significant and CAR T-restricted increase of selected cytokines. Interestingly, immunosuppressant TGF β1, expressed in all co-cultures, did not influence antitumor activity. The orthotopic NOD/SCID models using primary glioblastoma cells reproduced human histopathological features. Considering still-conflicting data on the delivery route for targeting brain tumors, we compared intracerebral versus intravenous CAR T injections. We report that the intracerebral route significantly increased the length of survival time in a dose-dependent manner, without any side effects. Collectively, the proposed anti-GD2 CAR can counteract human glioblastoma potentially opening a new therapeutic option for a still incurable cancer.
22 May 2019 in PLOS Pathogens
The Human Papillomavirus E7 oncoprotein plays an essential role in the development and maintenance of malignancy, which it achieves through targeting a number of critical cell control pathways. An important element in the ability of E7 to contribute towards cell transformation is the presence of a Casein Kinase II phospho-acceptor site within the CR2 domain of the protein. Phosphorylation is believed to enhance E7 interaction with a number of different cellular target proteins, and thereby increase the ability of E7 to enhance cell proliferation and induce malignancy. However, there is little information on how important this site in E7 is, once the tumour cells have become fully transformed. In this study, we have performed genome editing of the HPV-18 E7 CKII recognition site in C4-1 cervical tumour-derived cells. We first show that mutation of HPV18 E7 S32/S34 to A32/A34 abolishes CKII phosphorylation of E7, and subsequently we have isolated C4-1 clones containing these mutations in E7. The cells continue to proliferate, but are somewhat more slow-growing than wild type cells, reach lower saturation densities, and are also more susceptible to low nutrient conditions. These cells are severely defective in matrigel invasion assays, partly due to downregulation of matrix metalloproteases (MMPs). Mechanistically, we find that phosphorylation of E7 plays a direct role in the ability of E7 to activate AKT signaling, which in turn is required for optimal levels of MMP secretion. These results demonstrate that the E7 CKII phospho-acceptor site thus continues to play an important role for E7’s activity in cells derived from cervical cancers, and suggests that blocking this activity of E7 could be expected to have therapeutic potential. In this study we have used genome editing to mutate the HPV-18 E7 CKII phospho-acceptor site in cells derived from a cervical cancer. We demonstrate that this results in a decrease in cell proliferation and renders the cells particularly susceptible to low nutrient conditions. Furthermore these cells are defective in invasive potential and this appears linked to a decrease in the levels of secreted MMPs. Mechanistically this is linked directly to a role of the E7 CKII phospho-acceptor site in upregulating AKT signaling. These studies demonstrate that the E7 CKII site plays a direct role in maintaining a fully transformed phenotype, and indicates a novel function for this region of E7 in regulating AKT and the levels of secreted MMPs.
1 February 2024 in npj Precision Oncology
Glioblastoma (GBM) remains a deadly tumor. Treatment with chemo-radiotherapy and corticosteroids is known to impair the functionality of lymphocytes, potentially compromising the development of autologous CAR T cell therapies. We here generated pre-clinical investigations of autologous anti-GD2 CAR T cells tested against 2D and 3D models of GBM primary cells. We detected a robust antitumor effect, highlighting the feasibility of developing an autologous anti-GD2 CAR T cell-based therapy for GBM patients.
3 November 2026 in Cell Death & Disease
Ewing’s sarcoma (ES) is an aggressive cancer primarily affecting children and young adults. Although chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in hematologic malignancies, its efficacy against solid tumors such as ES remains limited. Our previous studies demonstrated the therapeutic potential of GD2 CAR T cells against brain tumors and showed that a truncated GD2 CAR enhances the tumor-targeting ability and antitumor efficacy of mesenchymal stromal/stem cells against metastatic ES. Here, we further investigated the therapeutic potential of GD2 CAR T cells in ES, a disease for which effective treatment options remain a significant unmet medical need. The antitumor activity of GD2 CAR T cells was assessed using different two-dimensional and three-dimensional in vitro ES models and an in vivo ES xenograft model. GD2 CAR T cells effectively killed ES cells in both two-dimensional and three-dimensional settings, including an ES cell line displaying low GD2 expression. In vivo, GD2 CAR T cells efficiently targeted localized ES tumors and counteracted tumor growth. CAR T cells infiltrated the tumors and were also detected in the spleen of treated mice. Overall, these findings support the efficacy of GD2 CAR T cells against both in vitro models and a localized in vivo model of ES. These findings underscore the potential of GD2 CAR T cell-based therapies to improve treatment outcomes in ES and other lethal GD2-positive malignancies.